Literature DB >> 21392603

Etanercept as adjunctive treatment for acute Kawasaki disease: study design and rationale.

Michael A Portman1, Aaron Olson, Brian Soriano, Nagib Dahdah, Richard Williams, Edward Kirkpatrick.   

Abstract

BACKGROUND: Kawasaki disease (KD) is a multisystem vasculitis affecting coronary arteries in children. Patients, refractory to standard treatment with intravenous immunoglobulin and aspirin, show higher rates of coronary artery dilation. Early tumor necrosis factor α receptor antagonism in KD may provide effective adjunctive therapy. STUDY
DESIGN: The EATAK trial is a multicenter, double-blind, randomized, and placebo-controlled trial intended to assess the efficacy of etanercept in reducing the intravenous immunoglobulin refractory rate during treatment of acute KD. Each arm will enroll 110 patients who will receive 3 doses of study drug over 2 weeks in conjunction with standard therapy. Coronary artery dilation parameters will serve as secondary end points. DISCUSSION: The EATAK trial will test a new paradigm for treatment of acute KD involving tumor necrosis factor α antagonism by etanercept.
Copyright © 2011 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21392603     DOI: 10.1016/j.ahj.2010.12.003

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  11 in total

1.  Partial response to anakinra in life-threatening Henoch-Schönlein purpura: case report.

Authors:  Erynn M Boyer; Martin Turman; Kathleen M O'Neil
Journal:  Pediatr Rheumatol Online J       Date:  2011-08-11       Impact factor: 3.054

2.  Etanercept With IVIg for Acute Kawasaki Disease: A Randomized Controlled Trial.

Authors:  Michael A Portman; Nagib S Dahdah; April Slee; Aaron K Olson; Nadine F Choueiter; Brian D Soriano; Sujatha Buddhe; Carolyn A Altman
Journal:  Pediatrics       Date:  2019-05-02       Impact factor: 7.124

Review 3.  Kawasaki disease: etiopathogenesis and novel treatment strategies.

Authors:  Shreya Agarwal; Devendra K Agrawal
Journal:  Expert Rev Clin Immunol       Date:  2016-09-13       Impact factor: 4.473

4.  FcγR gene copy number in Kawasaki disease and intravenous immunoglobulin treatment response.

Authors:  Robert Makowsky; Howard W Wiener; Travis S Ptacek; Miriam Silva; Aditi Shendre; Jeffrey C Edberg; Michael A Portman; Sadeep Shrestha
Journal:  Pharmacogenet Genomics       Date:  2013-09       Impact factor: 2.089

Review 5.  Epidemiology and management of Kawasaki disease.

Authors:  Nadia J C Luca; Rae S M Yeung
Journal:  Drugs       Date:  2012-05-28       Impact factor: 11.431

6.  TNF-α blockers for the treatment of Kawasaki disease in children.

Authors:  Noyuri Yamaji; Katharina da Silva Lopes; Tetsuo Shoda; Kazue Ishitsuka; Tohru Kobayashi; Erika Ota; Rintaro Mori
Journal:  Cochrane Database Syst Rev       Date:  2019-08-16

7.  DC-SIGN gene promoter variants and IVIG treatment response in Kawasaki disease.

Authors:  Michael A Portman; Howard W Wiener; Miriam Silva; Aditi Shendre; Sadeep Shrestha
Journal:  Pediatr Rheumatol Online J       Date:  2013-09-05       Impact factor: 3.054

Review 8.  Kawasaki disease: pathophysiology, clinical manifestations, and management.

Authors:  Victoria R Dimitriades; Amanda G Brown; Abraham Gedalia
Journal:  Curr Rheumatol Rep       Date:  2014-06       Impact factor: 4.686

Review 9.  Natriuretic Peptides in Kawasaki Disease: the Myocardial Perspective.

Authors:  Nagib Dahdah; Anne Fournier
Journal:  Diagnostics (Basel)       Date:  2013-01-10

10.  Incomplete Refractory Kawasaki Disease in an Infant-A Case Report and a Review of the Literature.

Authors:  Cristina O Mărginean; Lorena E Meliț; Liliana Gozar; Cristian Dan Mărginean; Maria O Mărginean
Journal:  Front Pediatr       Date:  2018-07-27       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.